Literature DB >> 12868557

Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report.

K Pulkkanen1, V Kataja, R Johansson.   

Abstract

In a few cases, gemcitabine (GCB) has been shown to result in systemic capillary leak syndrome (SCLS) in the treatment of non-small cell lung, pancreatic, and ovarian carcinomas. SCLS is a life-threatening condition characterized by increased capillary permeability resulting in manifest pulmonary and peripheral edema. Usually SCLS responds successfully to corticosteroid therapy and diuretics. We present a case where GCB treatment likely resulted in SCLS in a male patient with metastatic renal cell carcinoma (RCC) in the absence of predisposing cardiac, pleural, or pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12868557     DOI: 10.1179/joc.2003.15.3.287

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  3 in total

Review 1.  Anticancer Drug-Induced Capillary Leak Syndrome.

Authors:  Hassan Izzedine; Alexis Mathian; Zahir Amoura; Jia H Ng; Kenar D Jhaveri
Journal:  Kidney Int Rep       Date:  2022-02-25

2.  Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.

Authors:  Andrea Casadei Gardini; Michele Aquilina; Devil Oboldi; Alessandro Lucchesi; Silvia Carloni; Elena Tenti; Marco Angelo Burgio; Dino Amadori; Giovanni Luca Frassineti
Journal:  BMC Cancer       Date:  2013-11-12       Impact factor: 4.430

Review 3.  First line Immunotherapy for Non-Small Cell Lung Cancer.

Authors:  Nicola J Nasser; Miguel Gorenberg; Abed Agbarya
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.